Kyprolis

Chemical Namecarfilzomib
Dosage FormInjection (intravenous; 10 mg, 30 mg, 60 mg)
Drug ClassInhibitors
SystemBlood
CompanyAmgen
Approval Year2012

Indication

  • For the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone
  • For the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with dexamethasone
  • For the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with daratumumab and dexamethasone
  • Indicated for uses as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy
  • For the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with daratumumab and hyaluronidase-fihj and dexamethasone
Last updated on 4/19/2022

More on this drug: Clinical Trials

Document TitleYearSource
Kyprolis (carfilzomib) Prescribing Information.2021Onyx Pharmaceuticals, Inc., Thousand Oaks, CA

Have we missed a study, or would you like to comment on a study?